Soft tissue cancer, malignant (ICD10 C47 & C49): combined sexes
This is the EUROCARE definition for this group of cancers and includes peripheral nerves and autonomic nervous system (C47)
and other connective and soft tissue (C49)
Five-year relative survival by diagnosis year and age at diagnosis
|
Five-year relative survival (with 95% confidence interval) by diagnosis year |
EUROCARE-4 |
EUROCARE-4 |
||||||||||
|
Age at diagnosis |
1994-97 |
1998-2002 |
2003-2007 |
2007-2009 |
##2000-2002 |
##2000-2002 |
||||||
|
cohort |
cohort |
cohort |
*hybrid |
Ireland |
Europe average |
|||||||
|
all 15-99 |
53.1% |
59.2% |
63.3% |
64.9% |
||||||||
|
(unstandardized) |
(46.4-59.5%) |
(53.2-64.8%) |
(56.1-70.0%) |
(57.2-71.8%) |
||||||||
|
all 15-99 |
52.6% |
58.1% |
63.3% |
64.1% |
60.2% |
61.2% |
||||||
|
(age-standardized)# |
(38.2-66.0%) |
(45.2-69.7%) |
(48.5-75.6%) |
(47.5-77.5%) |
(52.4-69.3%) |
(58.3-64.2%) |
||||||
|
15-44 |
64.5% |
65.5% |
67.2% |
71.1% |
||||||||
|
(53.3-73.8%) |
(54.6-74.4%) |
(53.8-77.5%) |
(57.0-81.3%) |
|||||||||
|
45-54 |
54.3% |
59.6% |
73.7% |
73.0% |
||||||||
|
(38.6-67.8%) |
(44.9-71.7%) |
(58.7-84.2%) |
(56.2-84.4%) |
|||||||||
|
55-64 |
53.7% |
56.5% |
57.0% |
56.0% |
||||||||
|
(36.9-68.4%) |
(44.0-67.5%) |
(42.4-69.5%) |
(37.0-71.6%) |
|||||||||
|
65-74 |
38.6% |
52.4% |
65.3% |
71.3% |
||||||||
|
(25.5-52.3%) |
(39.8-64.2%) |
(50.7-77.3%) |
(53.5-84.6%) |
|||||||||
|
75-99 |
44.9% |
52.2% |
49.0% |
41.6% |
||||||||
|
(27.8-64.1%) |
(36.3-68.5%) |
(31.3-67.9%) |
(25.1-60.0%) |
|||||||||
|
Footnotes: |
|
|
*Hybrid estimate for 2007-2009 is the most up-to-date survival estimate and is based on follow-up of all cases alive at any point during this period, |
|
|
supplemented by follow-up 2005-2009 for cases diagnosed in 2005 or 2006 (to provide more reliable estimation of the first two years of survival). |
|
|
In practice, the hybrid estimate for 2007-2009 is similar to the most recent (incomplete) cohort, i.e. cases diagnosed 2003-2007, reflecting substantial overlap of data. |
|
|
# Age-standardized figures use the standard patient population proposed for this cancer by: |
|
|
Corazziari I., Quinn M. & Capocaccia R. 2004. Standard cancer patient population for age standardising survival ratios. Eur J Cancer 40: 2307-2316. |
|
|
(Population weights = age 15-44 x28000, 45-54 x17000, 55-64 x21000, 65-74 x20000, 75-99 x14000) |
|
|
## For comparison, the age-standardized average survival (2000-2002) is quoted for countries (including Ireland) that participated in the EUROCARE-4 study: |
|
|
Verdecchia A., Francisci S., Brenner H., et al. 2007. Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol 8: 784-796. |
|
|
Exclusions (as in EUROCARE): |
|
|
Patients aged <15 or >99 at diagnosis; death-certificate-only (DCO) and autopsy-only cases; second or subsequent malignancies in the same patient |
|
|
(or the less serious of two or more synchronously-diagnosed malignancies); in situ carcinomas and tumours of uncertain behaviour. |
|
|
© National Cancer Registry Ireland 2011 (October 2011) Relative survival statistics for Irish cancer patients |
|